CG
IONS icon

Cynosure Group’s Ionis Pharmaceuticals IONS Stock Holding History

Cynosure Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$422K Buy
+5,614
New +$443K 0.05% 126

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cynosure Group's IONS Position: Q1 2026 in Review

Cynosure Group opened a new position in Ionis Pharmaceuticals (IONS) in Q1 2026: 5,614 shares worth $422K. The stake represents 0.05% of the portfolio and ranks #126 among its holdings.

493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Cynosure Group held 5,614 shares of Ionis Pharmaceuticals worth $422K as of Q1 2026.
  • Ionis Pharmaceuticals was a new Cynosure Group position in Q1 2026.
  • Ionis Pharmaceuticals made up 0.05% of Cynosure Group's portfolio in Q1 2026, its #126 holding.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.